Loading

Commentary Open Access
Volume 1 | Issue 2 | DOI: https://doi.org/10.46439/breastcancer.1.007

How to inhibit breast cancer and breast cancer metastasis with Akt inhibitors: Lessons learned from studies in mice

  • 1Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA
  • 2Research & Development Section, Jesse Brown VA Medical Center, Chicago, IL 60612, USA
+ Affiliations - Affiliations

Corresponding Author

Nissim Hay, nhay@uic.edu

Received Date: July 05, 2021

Accepted Date: August 09, 2021

Abstract

The PI3K/Akt signaling pathway is frequently hyperactivated in different types of breast cancer. In the past two decades, major efforts have been made to develop inhibitors of this pathway to treat cancer patients. However, the most evolutionarily conserved function of this pathway is in cellular and organismal metabolism, which is hijacked by cancer cells. Thus, adverse metabolic consequences are expected when PI3K or Akt is targeted. These metabolic consequences, particularly hyperinsulinemia, could impede the efficacy of treatment. This review summarizes recent genetic studies in mice that could pave the way to efficient breast cancer and breast cancer metastasis treatment with Akt inhibitors.

Author Information X